Free Trial

Nautilus Biotechnology Q3 2024 Earnings Report

Nautilus Biotechnology logo
$1.93 +0.03 (+1.58%)
As of 01/17/2025 04:00 PM Eastern

Nautilus Biotechnology EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.17
Beat/Miss
Beat by +$0.04
One Year Ago EPS
-$0.13

Nautilus Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nautilus Biotechnology Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

Nautilus Biotechnology Earnings Headlines

The #1 Crypto for AI
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
See More Nautilus Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nautilus Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nautilus Biotechnology and other key companies, straight to your email.

About Nautilus Biotechnology

Nautilus Biotechnology (NASDAQ:NAUT), a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

View Nautilus Biotechnology Profile

More Earnings Resources from MarketBeat